Some studies have associated high ANXA2 expression levels to poor overall survival and disease-free survival, and advanced disease status in esophageal carcinoma (Ma et al., 2014), and NPC (Chen et al., 2015). This evidence concerns the gene ANXA2 and nasopharyngeal carcinoma.